<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004189</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067430</org_study_id>
    <secondary_id>UTHSC-IDD-98-34</secondary_id>
    <secondary_id>SACI-IDD-98-34</secondary_id>
    <secondary_id>NCI-T98-0069</secondary_id>
    <nct_id>NCT00004189</nct_id>
  </id_info>
  <brief_title>Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer</brief_title>
  <official_title>A Phase I and Pharmacokinetic Study of Sequences of NSC 655649 (Rebeccamycin Analogue) and Cisplatin Without and With Granulocyte Colony-Stimulating Factor Support Every 21 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of rebeccamycin analog and cisplatin with or without&#xD;
      filgrastim in treating patients who have advanced cancer. Drugs used in chemotherapy use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Combining more&#xD;
      than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may&#xD;
      increase the number of immune cells found in bone marrow or peripheral blood and may help a&#xD;
      person's immune system recover from the side effects of chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated doses of a rebeccamycin analogue and cisplatin with or&#xD;
      without filgrastim (G-CSF) in patients with advanced malignancies.&#xD;
&#xD;
      II. Determine the qualitative and quantitative toxicities of these regimens in these&#xD;
      patients.&#xD;
&#xD;
      III. Determine if the pharmacokinetics of a rebeccamycin analogue are affected by cisplatin&#xD;
      and if there are sequence dependent pharmacokinetic effects.&#xD;
&#xD;
      IV. Assess any antitumor effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study of a rebeccamycin analogue and&#xD;
      cisplatin.&#xD;
&#xD;
      Part I (previously untreated or minimally pretreated patients): The first patient of each&#xD;
      cohort receives cisplatin IV over 1 hour followed 2 hours later by a rebeccamycin analogue IV&#xD;
      over 1 hour on day 1. The second patient in the same cohort receives the same drugs in the&#xD;
      reverse order. The drug sequence for each additional patient within the same cohort is&#xD;
      alternated with reference to the preceding patient. During each subsequent course, the study&#xD;
      drugs are administered to each patient in the reverse order as compared to the prior course.&#xD;
      Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Dose escalation is initially performed without filgrastim (G-CSF). Cohorts of 4-6 patients&#xD;
      receive escalating doses of a rebeccamycin analogue and cisplatin until the maximum tolerated&#xD;
      dose (MTD) of each drug is determined. The MTD is defined as the highest dose at which less&#xD;
      than 2 of 6 patients experience dose limiting toxicity (DLT). If 2 of the first 6 patients&#xD;
      experience DLT, then dose escalation proceeds in combination with G-CSF treatment. Patients&#xD;
      receive G-CSF subcutaneously daily beginning on day 2 and continuing until blood counts have&#xD;
      recovered for 2 days or until approximately day 15. Cohorts of 4-6 patients receive&#xD;
      escalating doses of a rebeccamycin analogue and cisplatin as above. The MTD is defined as&#xD;
      above.&#xD;
&#xD;
      Part II (heavily pretreated patients): Heavily pretreated patients receive a rebeccamycin&#xD;
      analogue and cisplatin starting at 2 dose levels preceding the MTD from part I.&#xD;
&#xD;
      Patients are followed for at least 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lymphoma</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>becatecarin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven advanced malignancy that is refractory to prior&#xD;
             therapy or unlikely to benefit from standard therapy (e.g., chemotherapy,&#xD;
             radiotherapy, and surgery)&#xD;
&#xD;
               -  Part I: Previously untreated OR minimally pretreated&#xD;
&#xD;
                    -  Ineligible for part I and considered heavily pretreated if:&#xD;
&#xD;
                         -  Prior radiotherapy to wide ports involving the pelvis or at least 25%&#xD;
                            of bone marrow&#xD;
&#xD;
                         -  Greater than 6 courses of prior combination chemotherapy including&#xD;
                            alkylating agent&#xD;
&#xD;
                         -  Prior nitrosoureas or mitomycin&#xD;
&#xD;
                         -  Widespread bone metastases with bone marrow involvement by bone marrow&#xD;
                            biopsy (positive bilateral bone marrow biopsy for lymphoma patients)&#xD;
&#xD;
               -  Part II: Heavily pretreated as defined above&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 mg/dL&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No clinically significant, multifocal, uncontrolled cardiac dysrhythmias&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active serious infection&#xD;
&#xD;
          -  No clinically severe peripheral neuropathy (grade 1 or worse)&#xD;
&#xD;
          -  No nonmalignant medical condition that would preclude compliance or increase risk of&#xD;
             participation in study&#xD;
&#xD;
          -  No hypersensitivity to E. coli derived drug preparations&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No other concurrent colony stimulating factors for prophylactic purposes&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks since prior nitrosoureas and&#xD;
             mitomycin) and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No chronic oral corticosteroids&#xD;
&#xD;
          -  No concurrent corticosteroids except as prophylactic antiemetic&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 1 month since prior investigational agent&#xD;
&#xD;
          -  No prophylactic oral or IV antibiotics for neutropenia unless fever present&#xD;
&#xD;
          -  No other concurrent anticancer treatment or investigational agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Hammond, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Lutheran Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2003</verification_date>
  <study_first_submitted>January 21, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

